by Dr. G. Pepper | Aug 24, 2011 | diabetes, diet, diet and weight loss, general health & nutrition, metabolism, misc, Uncategorized, weight loss
A potential new treatment for type 2 diabetes, dapagliflozin, recently failed to gain approval from the FDA. What makes this rejection noteworthy is that the new medication works by a completely new mechanism causing the kidney to excrete sugar from the blood into the...
by Dr. G. Pepper | May 16, 2011 | diabetes, diet, general health & nutrition, health, metabolism, weight gain
(I don’t think so, and here’s why.) The FDA just announced its approval of linagliptin (Tradjenta), a new diabetes medication developed by Eli Lilly and Company and Boehringer Inglheim. Linagliptin is the third drug to be approved in the class of medications...
by Dr. G. Pepper | Jan 18, 2010 | diabetes, diet and weight loss, general health & nutrition, health
New Diabetes Treatment Guidelines Lack Credibility: Recently the American Academy of Clinical Endocrinologists issued new treatment guidelines for treating Type 2 Diabetes. Complex medical guidelines are often referred to as a treatment algorithm. One of the stated...
by Dr. G. Pepper | Jun 16, 2009 | diabetes, general health & nutrition, health, metabolism
This post is the third in a series under the title: 2009. Another Troubled Year for Endocrinologists. This year the FDA has instituted new standards for diabetes drugs coming up for approval. These new standards require that each new drug prior to approval must...
by Gary Pepper M.D. | Oct 19, 2007 | diabetes
Two of the newest diabetes treatments suffered major set-backs this week. Endocrinologists across the U.S. received a notice today that Exubera, the inhaled form of insulin, would soon become unavailable. This is because Pfizer, the pharmaceutical giant which has sole...
Loading ...